Literature DB >> 24914931

CD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques.

Naoki Saito1, Hideto Chono1, Hiroaki Shibata2, Naohide Ageyama2, Yasuhiro Yasutomi2, Junichi Mineno1.   

Abstract

MazF, an endoribonuclease encoded by Escherichia coli, specifically cleaves the ACA (adenine-cytosine-adenine) sequence of single-stranded RNAs. Conditional expression of MazF under the control of the HIV-1 LTR promoter rendered CD4(+) T cells resistant to HIV-1 replication without affecting cell growth. To investigate the safety, persistence and efficacy of MazF-modified CD4(+) T cells in a nonhuman primate model in vivo, rhesus macaques were infected with a pathogenic simian/human immunodeficiency virus (SHIV) and transplanted with autologous MazF-modified CD4(+) T cells. MazF-modified CD4(+) T cells were clearly detected throughout the experimental period of more than 6 months. The CD4(+) T cell count values increased in all four rhesus macaques. Moreover, the transplantation of the MazF-modified CD4(+) T cells was not immunogenic, and did not elicit cellular or humoral immune responses. These data suggest that the autologous transplantation of MazF-modified CD4(+) T cells in the presence of SHIV is effective, safe and not immunogenic, indicating that this is an attractive strategy for HIV-1 gene therapy.

Entities:  

Year:  2014        PMID: 24914931      PMCID: PMC4078760          DOI: 10.1038/mtna.2014.20

Source DB:  PubMed          Journal:  Mol Ther Nucleic Acids        ISSN: 2162-2531            Impact factor:   10.183


  37 in total

1.  Polyclonal long-term repopulating stem cell clones in a primate model.

Authors:  Manfred Schmidt; Philipp Zickler; Gesa Hoffmann; Sebastian Haas; Manuela Wissler; Arne Muessig; John F Tisdale; Ken Kuramoto; Robert G Andrews; Tong Wu; Hans-Peter Kiem; Cynthia E Dunbar; Christof von Kalle
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

Review 2.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Acquisition of HIV-1 resistance in T lymphocytes using an ACA-specific E. coli mRNA interferase.

Authors:  Hideto Chono; Kazuya Matsumoto; Hiroshi Tsuda; Naoki Saito; Karim Lee; Sujeong Kim; Hiroaki Shibata; Naohide Ageyama; Keiji Terao; Yasuhiro Yasutomi; Junichi Mineno; Sunyoung Kim; Masayori Inouye; Ikunoshin Kato
Journal:  Hum Gene Ther       Date:  2010-12-12       Impact factor: 5.695

4.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.

Authors:  Ming-Jie Li; James Kim; Shirley Li; John Zaia; Jiing-Kuan Yee; Joseph Anderson; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2005-08-22       Impact factor: 11.454

Review 5.  AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

Authors:  Matthew C Cheung; Liron Pantanowitz; Bruce J Dezube
Journal:  Oncologist       Date:  2005 Jun-Jul

6.  Development and homeostasis of T cell memory in rhesus macaque.

Authors:  Christine J Pitcher; Shoko I Hagen; Joshua M Walker; Richard Lum; Bridget L Mitchell; Vernon C Maino; Michael K Axthelm; Louis J Picker
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

7.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

Review 8.  Gene therapy: a bold direction for HIV-1 treatment.

Authors:  N Sarver; J Rossi
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

9.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

10.  In vivo safety and persistence of endoribonuclease gene-transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy model.

Authors:  Hideto Chono; Naoki Saito; Hiroshi Tsuda; Hiroaki Shibata; Naohide Ageyama; Keiji Terao; Yasuhiro Yasutomi; Junichi Mineno; Ikunoshin Kato
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

View more
  2 in total

Review 1.  Tumor vascular infarction: prospects and challenges.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Nosratollah Zarghami
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

2.  Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals.

Authors:  Jeffrey M Jacobson; Julie K Jadlowsky; Simon F Lacey; Joseph A Fraietta; Gabriela Plesa; Hideto Chono; Dong H Lee; Irina Kulikovskaya; Chelsie Bartoszek; Fang Chen; Lifeng Tian; Alexander Dimitri; Bruce L Levine; Elizabeth A Veloso; Wei-Ting Hwang; Carl H June
Journal:  Mol Ther       Date:  2020-11-11       Impact factor: 11.454

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.